AIM ImmunoTech Inc.
July 28, 2025 - by Joey Ramson
$AIM gapped above its 50 and 200DMA and is the leader of the Prism MarketView Biotech index as it reported Positive data from its Phase 2 study evaluating Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
